Your browser doesn't support javascript.
loading
COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.
Peremiquel-Trillas, Paula; Saura-Lázaro, Anna; Benavente-Moreno, Yolanda; Casabonne, Delphine; Loureiro, Eva; Cabrera, Sandra; Duran, Angela; Garrote, Lidia; Brao, Immaculada; Trelis, Jordi; Galán, Maica; Soler, Francesc; Julià, Joaquim; Cortasa, Dolça; Domínguez, Maria Ángeles; Albasanz-Puig, Adaia; Gudiol, Carlota; Ramírez-Tarruella, Dolors; Muniesa, Joan; Rivas, Juan Pedro; Muñoz-Montplet, Carles; Sedano, Ana; Plans, Àngel; Calvo-Cerrada, Beatriz; Calle, Candela; Clopés, Ana; Carnicer-Pont, Dolors; Alemany, Laia; Fernández, Esteve.
Affiliation
  • Peremiquel-Trillas P; Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Saura-Lázaro A; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Benavente-Moreno Y; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Casabonne D; School of Medicine and Clinical Sciences, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.
  • Loureiro E; Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Cabrera S; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Duran A; Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Garrote L; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Brao I; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Trelis J; Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Galán M; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Soler F; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Julià J; Computer Science Services, Technology & Physics, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Cortasa D; Computational Science and Artificial Intelligence, Schoolof Computer Science of Coruña, University of Coruña (UDC), Coruña, Spain.
  • Domínguez MÁ; Research Nursing Department, Institut Català d'Oncologia (ICO), Badalona, Spain.
  • Albasanz-Puig A; Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Gudiol C; Nursing Department, Institut Català d'Oncologia, Badalona, Spain.
  • Ramírez-Tarruella D; Nursing Department, Institut Català d'Oncologia (ICO), Girona, Spain.
  • Muniesa J; School of Medicine and Clinical Sciences, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.
  • Rivas JP; Palliative Care Department and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Muñoz-Montplet C; Esofagogastric Tumours Functional Unit and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
  • Sedano A; Pharmacy Service and Medical Director, Institut Català d'Oncologia (ICO), Girona, Spain.
  • Plans À; Palliative Care Department and Medical Director, Institut Català d'Oncologia (ICO), Badalona, Spain.
  • Calvo-Cerrada B; School of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
  • Calle C; Medical Director, Institut català d'Oncologia, Tarragona, Spain.
  • Clopés A; Microbiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
  • Carnicer-Pont D; Infectious Diseases Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Alemany L; Department of Pathology Experimental Therapeutics, Universitat de Barcelona, L'Hosìtalet de Llobregat, Spain.
  • Fernández E; Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
BMJ Open ; 12(4): e056637, 2022 04 21.
Article in En | MEDLINE | ID: mdl-35450905
ABSTRACT

OBJECTIVES:

Patients with cancer are at higher risk for severe COVID-19 infection. COVID-19 surveillance of workers in oncological centres is crucial to assess infection burden and prevent transmission. We estimate the SARS-CoV-2 seroprevalence among healthcare workers (HCWs) of a comprehensive cancer centre in Catalonia, Spain, and analyse its association with sociodemographic characteristics, exposure factors and behaviours.

DESIGN:

Cross-sectional study (21 May 2020-26 June 2020).

SETTING:

A comprehensive cancer centre (Institut Català d'Oncologia) in Catalonia, Spain.

PARTICIPANTS:

All HCWs (N=1969) were invited to complete an online self-administered epidemiological survey and provide a blood sample for SARS-CoV-2 antibodies detection. PRIMARY OUTCOME

MEASURE:

Prevalence (%) and 95% CIs of seropositivity together with adjusted prevalence ratios (aPR) and 95% CI were estimated.

RESULTS:

A total of 1266 HCWs filled the survey (participation rate 64.0%) and 1238 underwent serological testing (97.8%). The median age was 43.7 years (p25-p75 34.8-51.0 years), 76.0% were female, 52.0% were nursing or medical staff and 79.0% worked on-site during the pandemic period. SARS-CoV-2 seroprevalence was 8.9% (95% CI 7.44% to 10.63%), with no differences by age and sex. No significant differences in terms of seroprevalence were observed between onsite workers and teleworkers. Seropositivity was associated with living with a person with COVID-19 (aPR 3.86, 95% CI 2.49 to 5.98). Among on-site workers, seropositive participants were twofold more likely to be nursing or medical staff. Nursing and medical staff working in a COVID-19 area showed a higher seroprevalence than other staff (aPR 2.45, 95% CI 1.08 to 5.52).

CONCLUSIONS:

At the end of the first wave of the pandemic in Spain, SARS-CoV-2 seroprevalence among Institut Català d'Oncologia HCW was lower than the reported in other Spanish hospitals. The main risk factors were sharing household with infected people and contact with COVID-19 patients and colleagues. Strengthening preventive measures and health education among HCW is fundamental.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: BMJ Open Year: 2022 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: BMJ Open Year: 2022 Document type: Article Affiliation country: Spain